Ezetimibe use and mortality after myocardial infarction: A nationwide cohort study
American Journal of Preventive CardiologyBackground: The inhibition of intestinal cholesterol absorption by ezetimibe improves outcomes after myocardial infarction (MI), yet real-world data on ezetimibe is scarce. We studied the usage of ezetimibe and association with outcome after MI. Methods:
Ville Kytö, Aleksi Tornio
doaj +1 more source
Adding ezetimibe to statin therapy: latest evidence and clinical implications
, 2018 Background: Statins are the hypolipemic treatment of choice for hyperlipidemia with confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients.
Marija Vavlukis, Ana Vavlukis
core +1 more source
Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft [PDF]
, 2012 BackgroundThe selective cholesterol transport inhibitor ezetimibe is widely used to prevent development of atherosclerosis in patients with hypercholesterolemia.
Maekawa, Takashi +3 more
core +1 more source
Ezetimibe: Use, costs, and adverse events in Australia
, 2017 Aim: To analyze the subsidized use and reported adverse events of ezetimibe, used to lower cholesterol, in Australia over the 11 years following its inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2004.
Martin, JH +4 more
core +1 more source
Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between alpha-tocopherol and ezetimibe [PDF]
, 2017 Tocopherol is used not only as an ethical drug but also as a supplement. In 2008, it was reported that alpha-tocopherol is partly transported via an intestinal cholesterol transporter, Niemann-Pick C1-Like 1 (NPC1L1).
Shunsuke Nashimoto +7 more
core +1 more source
Square-wave voltammetric determination of ezetimibe [PDF]
, 2011 voltammetry (SWV) at a hanging mercury-drop electrode (HMDE) in electrolytes of different pH. Ezetimibe gave rise to a single voltammetric peak in the potential interval from -1290 to - 1322 mV depending on ezetimibe concentration within the entire pH ...
Özaltın, Nuran, Yola, Mehmet Lütfi
core +2 more sources
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
Journal of Lipid Research, 2007 The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis.
Dawn E. Telford +5 more
doaj +1 more source
Lipids in Health and Disease, 2020 Background The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption.
Bin Xia +9 more
doaj +1 more source
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Advanced Science, EarlyView.Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng +12 more
wiley +1 more source
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]
Journal of Lipid Research, 2011 Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks ...
Brandon Ason +18 more
doaj +1 more source